The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)

M Bushati, K P Rovers, A Sommariva, P H Sugarbaker, D L Morris, Y Yonemura, C A Quadros, S P Somashekhar, W Ceelen, P Dubé, Y Li, V J Verwaal, O Glehen, P Piso, J Spiliotis, M C C Teo, S González-Moreno, P H Cashin, K Lehmann, M DeracoB Moran, I H J T de Hingh

Research output: Contribution to journalArticle

Abstract

BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.

METHODS: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and countrywide practice.

RESULTS: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.

CONCLUSION: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.

Original languageEnglish
Pages (from-to)1942-1948
Number of pages7
JournalEuropean Journal of Surgical Oncology
Volume44
Issue number12
DOIs
Publication statusPublished - Dec 2018

Fingerprint

Neoplasm Metastasis
Drug Therapy
Surveys and Questionnaires
Therapeutics
Guidelines

Keywords

  • Colorectal Neoplasms/pathology
  • Combined Modality Therapy
  • Cytoreduction Surgical Procedures/methods
  • Humans
  • Hyperthermia, Induced/methods
  • Internet
  • Peritoneal Neoplasms/secondary
  • Practice Patterns, Physicians'/statistics & numerical data
  • Surveys and Questionnaires
  • Treatment Outcome

Cite this

The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases : Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). / Bushati, M; Rovers, K P; Sommariva, A; Sugarbaker, P H; Morris, D L; Yonemura, Y; Quadros, C A; Somashekhar, S P; Ceelen, W; Dubé, P; Li, Y; Verwaal, V J; Glehen, O; Piso, P; Spiliotis, J; Teo, M C C; González-Moreno, S; Cashin, P H; Lehmann, K; Deraco, M; Moran, B; de Hingh, I H J T.

In: European Journal of Surgical Oncology, Vol. 44, No. 12, 12.2018, p. 1942-1948.

Research output: Contribution to journalArticle

Bushati, M, Rovers, KP, Sommariva, A, Sugarbaker, PH, Morris, DL, Yonemura, Y, Quadros, CA, Somashekhar, SP, Ceelen, W, Dubé, P, Li, Y, Verwaal, VJ, Glehen, O, Piso, P, Spiliotis, J, Teo, MCC, González-Moreno, S, Cashin, PH, Lehmann, K, Deraco, M, Moran, B & de Hingh, IHJT 2018, 'The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)', European Journal of Surgical Oncology, vol. 44, no. 12, pp. 1942-1948. https://doi.org/10.1016/j.ejso.2018.07.003
Bushati, M ; Rovers, K P ; Sommariva, A ; Sugarbaker, P H ; Morris, D L ; Yonemura, Y ; Quadros, C A ; Somashekhar, S P ; Ceelen, W ; Dubé, P ; Li, Y ; Verwaal, V J ; Glehen, O ; Piso, P ; Spiliotis, J ; Teo, M C C ; González-Moreno, S ; Cashin, P H ; Lehmann, K ; Deraco, M ; Moran, B ; de Hingh, I H J T. / The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases : Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). In: European Journal of Surgical Oncology. 2018 ; Vol. 44, No. 12. pp. 1942-1948.
@article{b5109efa8cba4ab9af7eece7aebc59b4,
title = "The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)",
abstract = "BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.METHODS: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and countrywide practice.RESULTS: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.CONCLUSION: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.",
keywords = "Colorectal Neoplasms/pathology, Combined Modality Therapy, Cytoreduction Surgical Procedures/methods, Humans, Hyperthermia, Induced/methods, Internet, Peritoneal Neoplasms/secondary, Practice Patterns, Physicians'/statistics & numerical data, Surveys and Questionnaires, Treatment Outcome",
author = "M Bushati and Rovers, {K P} and A Sommariva and Sugarbaker, {P H} and Morris, {D L} and Y Yonemura and Quadros, {C A} and Somashekhar, {S P} and W Ceelen and P Dub{\'e} and Y Li and Verwaal, {V J} and O Glehen and P Piso and J Spiliotis and Teo, {M C C} and S Gonz{\'a}lez-Moreno and Cashin, {P H} and K Lehmann and M Deraco and B Moran and {de Hingh}, {I H J T}",
note = "Copyright {\circledC} 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.",
year = "2018",
month = "12",
doi = "10.1016/j.ejso.2018.07.003",
language = "English",
volume = "44",
pages = "1942--1948",
journal = "European Journal of Surgical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases

T2 - Results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI)

AU - Bushati, M

AU - Rovers, K P

AU - Sommariva, A

AU - Sugarbaker, P H

AU - Morris, D L

AU - Yonemura, Y

AU - Quadros, C A

AU - Somashekhar, S P

AU - Ceelen, W

AU - Dubé, P

AU - Li, Y

AU - Verwaal, V J

AU - Glehen, O

AU - Piso, P

AU - Spiliotis, J

AU - Teo, M C C

AU - González-Moreno, S

AU - Cashin, P H

AU - Lehmann, K

AU - Deraco, M

AU - Moran, B

AU - de Hingh, I H J T

N1 - Copyright © 2018 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.

PY - 2018/12

Y1 - 2018/12

N2 - BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.METHODS: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and countrywide practice.RESULTS: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.CONCLUSION: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.

AB - BACKGROUND: At present, selected patients with resectable colorectal peritoneal metastases (CRC-PM) are increasingly treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). The aim of this study was to investigate the current worldwide practice.METHODS: HIPEC experts from 19 countries were invited through the Peritoneal Surface Oncology Group International (PSOGI) to complete an online survey concerning their personal expertise and current hospital and countrywide practice.RESULTS: It is estimated that currently more than 3800 patients with CRC-PM (synchronous and metachronous) are annually treated with CRS and HIPEC in 430 centers. Integration of CRS and HIPEC in national guidelines varies, resulting in large treatment disparities between countries. Amongst the experts, there was general agreement on issues related to indication, surgical technique and follow up but less on systemic chemotherapy or proactive strategies.CONCLUSION: This international survey demonstrates that CRS and HIPEC is now performed on a large scale for CRC-PM patients. Variation in treatment may result in heterogeneity in surgical and oncological outcomes, emphasising the necessity to reach consensus on several issues of this comprehensive procedure. Future initiatives directed at achieving an international consensus statement are needed.

KW - Colorectal Neoplasms/pathology

KW - Combined Modality Therapy

KW - Cytoreduction Surgical Procedures/methods

KW - Humans

KW - Hyperthermia, Induced/methods

KW - Internet

KW - Peritoneal Neoplasms/secondary

KW - Practice Patterns, Physicians'/statistics & numerical data

KW - Surveys and Questionnaires

KW - Treatment Outcome

U2 - 10.1016/j.ejso.2018.07.003

DO - 10.1016/j.ejso.2018.07.003

M3 - Article

C2 - 30075978

VL - 44

SP - 1942

EP - 1948

JO - European Journal of Surgical Oncology

JF - European Journal of Surgical Oncology

SN - 0748-7983

IS - 12

ER -